90,034 Shares in Anavex Life Sciences Corp. (NASDAQ:AVXL) Bought by Virtu Financial LLC

Virtu Financial LLC bought a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) in the 4th quarter, Holdings Channel.com reports. The fund bought 90,034 shares of the biotechnology company’s stock, valued at approximately $967,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Orion Capital Management LLC grew its stake in Anavex Life Sciences by 666.7% during the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock worth $65,000 after purchasing an additional 10,000 shares in the last quarter. PVG Asset Management Corp acquired a new position in Anavex Life Sciences during the 3rd quarter worth $74,000. Atria Investments Inc acquired a new position in Anavex Life Sciences during the 3rd quarter worth $76,000. BNP Paribas Financial Markets grew its stake in Anavex Life Sciences by 97.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock worth $86,000 after purchasing an additional 7,421 shares in the last quarter. Finally, Erste Asset Management GmbH acquired a new position in Anavex Life Sciences during the 3rd quarter worth $102,000. 31.55% of the stock is owned by institutional investors and hedge funds.

Anavex Life Sciences Price Performance

Shares of NASDAQ AVXL opened at $9.74 on Monday. The company has a market capitalization of $828.52 million, a price-to-earnings ratio of -17.71 and a beta of 0.94. The business has a 50-day moving average of $9.10 and a two-hundred day moving average of $8.18. Anavex Life Sciences Corp. has a 1 year low of $3.25 and a 1 year high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03. As a group, equities research analysts expect that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on AVXL shares. HC Wainwright reaffirmed a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a report on Tuesday, February 18th. D. Boral Capital reaffirmed a “buy” rating and set a $46.00 price target on shares of Anavex Life Sciences in a report on Wednesday, February 12th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.